Technology evaluation: cantuzumab mertansine, ImmunoGen.

Abstract

ImmunoGen is developing cantuzumab mertansine, in which the CanAg antigen-targeted humanized antibody C242 is conjugated to the company's proprietary cytotoxic agent, DM1, using ImmunoGen's tumor-activated prodrug technology. Cantuzumab mertansine is undergoing phase II trials for the potential treatment of CanAg-expressing cancers, including pancreatic and colorectal cancers and non-small-cell lung cancer.

• Authors: Suzanne V Smith
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 6 Issue 6 Pg. 666-74 (Dec 2004) ISSN: 1464-8431 [Print] England
• PMID: 15663331 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Drugs, Investigational
• Maytansine
• cantuzumab mertansine

Topics

• Animals
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic (statistics & numerical data)
• Drug Evaluation (methods)
• Drugs, Investigational (chemistry, pharmacology, therapeutic use)
• Humans
• Maytansine (analogs & derivatives, chemistry, pharmacology, therapeutic use)
• Technology, Pharmaceutical (methods)